Underground Adaptation to a Hostile environment: Acute Myeloid Leukemia vs. Natural Killer Cells

被引:23
作者
Dulphy, Nicolas [1 ,2 ,3 ]
Chretien, Anne-Sophie [4 ]
Khaznadar, Zena [1 ,2 ]
Fauriat, Cyril [4 ]
Nanbakhsh, Arash [5 ]
Caignard, Anne [1 ,2 ]
Chouaib, Salem [5 ]
Olive, Daniel [4 ]
Toubert, Antoine [1 ,2 ,3 ]
机构
[1] INSERM, UMRS 1160, Paris, France
[2] Univ Paris Diderot, Sorbonne Paris Cite, U 1160, Paris, France
[3] Hop St Louis, AP HP, Lab Immunol & Histocompatibil, Paris, France
[4] Aix Marseille Univ, CNRS, CRCM,Equipe Immunite & Canc, INSERM,Inst Paoli Calmettes,U1068,UM 105,UMR7258, Marseille, France
[5] INSERM, U 753, Villejuif, France
关键词
natural killer cells; acute myeloid leukemia; immunoediting; natural killer receptors; immune escape of cancer; aging and cancer; GENE-EXPRESSION PROFILES; INNATE IMMUNE-SYSTEM; HEMATOPOIETIC STEM-CELLS; NKG2D LIGAND EXPRESSION; MOUSE LYMPHOID-CELLS; KIR ANTIBODY IPH2101; I-RELATED CHAIN; NK CELLS; DNA-DAMAGE; UP-REGULATION;
D O I
10.3389/fimmu.2016.00094
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Acute myeloid leukemia (AML) is a heterogeneous group of malignancies which incidence increases with age. The disease affects the differentiation of hematopoietic stem or precursor cells in the bone marrow and can be related to abnormal cytogenetic and/or specific mutational patterns. AML blasts can be sensitive to natural killer (NK) cell antitumor response. However, NK cells are frequently defective in AML patients leading to tumor escape. NK cell defects affect not only the expression of the activating NK receptors, including the natural cytotoxicity receptors, the NK group 2, member D, and the DNAX accessory molecule-1, but also cytotoxicity and IFN-gamma release. Such perturbations in NK cell physiology could be related to the adaptation of the AML to the immune pressure and more generally to patient's clinical features. Various mechanisms are potentially involved in the inhibition of NK-cell functions in AML, including defects in the normal lymphopoiesis, reduced expression of activating receptors through cell-to-cell contacts, and production of immunosuppressive soluble agents by leukemic blasts. Therefore, the continuous cross-talk between AML and NK cells participates to the leukemia immune escape and eventually to patient's relapse. Methods to restore or stimulate NK cells seem to be attractive strategies to treat patients once the complete remission is achieved. Moreover, our capacity in stimulating the NK cell functions could lead to the development of preemptive strategies to eliminate leukemia-initiating cells before the emergence of the disease in elderly individuals presenting preleukemic mutations in hematopoietic stem cells.
引用
收藏
页数:15
相关论文
共 187 条
[1]   Cytokine therapy reverses NK cell anergy in MHC-deficient tumors [J].
Ardolino, Michele ;
Azimi, Camillia S. ;
Iannello, Alexandre ;
Trevino, Troy N. ;
Horan, Lucas ;
Zhang, Lily ;
Deng, Weiwen ;
Ring, Aaron M. ;
Fischer, Suzanne ;
Garcia, K. Christopher ;
Raulet, David H. .
JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (11) :4781-4794
[2]   DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction [J].
Ardolino, Michele ;
Zingoni, Alessandra ;
Cerboni, Cristina ;
Cecere, Francesca ;
Soriani, Alessandra ;
Iannitto, Maria Luisa ;
Santoni, Angela .
BLOOD, 2011, 117 (18) :4778-4786
[3]  
Baek HJ, 2013, ANTICANCER RES, V33, P2011
[4]   Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells [J].
Barao, I ;
Hanash, AM ;
Hallett, W ;
Welniak, LA ;
Sun, K ;
Redelman, D ;
Blazar, BR ;
Levy, RB ;
Murphy, WJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (14) :5460-5465
[5]   Phase 1 study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers [J].
Bartlett, JB ;
Michael, A ;
Clarke, IA ;
Dredge, K ;
Nicholson, S ;
Kristeleit, H ;
Polychronis, A ;
Pandha, H ;
Muller, GW ;
Stirling, DI ;
Zeldis, J ;
Dalgleish, AG .
BRITISH JOURNAL OF CANCER, 2004, 90 (05) :955-961
[6]   Identification of a cellular ligand for the natural cytotoxicity receptor NKp44 [J].
Baychelier, Florence ;
Sennepin, Alexis ;
Ermonval, Myriam ;
Dorgham, Karim ;
Debre, Patrice ;
Vieillard, Vincent .
BLOOD, 2013, 122 (17) :2935-2942
[7]   Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression [J].
Bellucci, Roberto ;
Martin, Allison ;
Bommarito, Davide ;
Wang, Kathy ;
Hansen, Steen H. ;
Freeman, Gordon J. ;
Ritz, Jerome .
ONCOIMMUNOLOGY, 2015, 4 (06)
[8]   A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma [J].
Benson, Don M., Jr. ;
Cohen, Adam D. ;
Jagannath, Sundar ;
Munshi, Nikhil C. ;
Spitzer, Gary ;
Hofmeister, Craig C. ;
Efebera, Yvonne A. ;
Andre, Pascale ;
Zerbib, Robert ;
Caligiuri, Michael A. .
CLINICAL CANCER RESEARCH, 2015, 21 (18) :4055-4061
[9]   A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma [J].
Benson, Don M., Jr. ;
Hofmeister, Craig C. ;
Padmanabhan, Swaminathan ;
Suvannasankha, Attaya ;
Jagannath, Sundar ;
Abonour, Rafat ;
Bakan, Courtney ;
Andre, Pascale ;
Efebera, Yvonne ;
Tiollier, Jerome ;
Caligiuri, Michael A. ;
Farag, Sherif S. .
BLOOD, 2012, 120 (22) :4324-4333
[10]   IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect [J].
Benson, Don M., Jr. ;
Bakan, Courtney E. ;
Zhang, Shuhong ;
Collins, Shauna M. ;
Liang, Jing ;
Srivastava, Shivani ;
Hofmeister, Craig C. ;
Efebera, Yvonne ;
Andre, Pascale ;
Romagne, Francois ;
Blery, Mathieu ;
Bonnafous, Cecile ;
Zhang, Jianying ;
Clever, David ;
Caligiuri, Michael A. ;
Farag, Sherif S. .
BLOOD, 2011, 118 (24) :6387-6391